These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26910074)

  • 41. Prospects of miRNA-based therapy for pancreatic cancer.
    Pai P; Rachagani S; Are C; Batra SK
    Curr Drug Targets; 2013 Sep; 14(10):1101-9. PubMed ID: 23834151
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroRNAs in pancreatic malignancy: progress and promises.
    Srivastava SK; Arora S; Singh S; Bhardwaj A; Averett C; Singh AP
    Cancer Lett; 2014 Jun; 347(2):167-74. PubMed ID: 24561061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pancreatic cancer: understanding and overcoming chemoresistance.
    Wang Z; Li Y; Ahmad A; Banerjee S; Azmi AS; Kong D; Sarkar FH
    Nat Rev Gastroenterol Hepatol; 2011 Jan; 8(1):27-33. PubMed ID: 21102532
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview.
    Quiñonero F; Mesas C; Doello K; Cabeza L; Perazzoli G; Jimenez-Luna C; Rama AR; Melguizo C; Prados J
    Cancer Biol Med; 2019 Nov; 16(4):688-699. PubMed ID: 31908888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer.
    Funamizu N; Honjo M; Tamura K; Sakamoto K; Ogawa K; Takada Y
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Two Available RNA Extraction Protocols for microRNA Amplification in Serum Samples.
    Bergallo M; Gambarino S; Martino S; Montin D; Montanari P; Galliano I; Tovo PA
    J Clin Lab Anal; 2016 Jul; 30(4):277-83. PubMed ID: 25853736
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma.
    Diab M; Muqbil I; Mohammad RM; Azmi AS; Philip PA
    J Clin Med; 2016 Jun; 5(6):. PubMed ID: 27322337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment.
    Danquah M; Singh S; Behrman SW; Mahato RI
    Expert Opin Drug Deliv; 2012 Dec; 9(12):1443-7. PubMed ID: 22954290
    [No Abstract]   [Full Text] [Related]  

  • 49. [Pancreatic cancer--mechanisms of chemoresistance].
    Borowa-Mazgaj B
    Postepy Hig Med Dosw (Online); 2016 Mar; 70():169-79. PubMed ID: 26943314
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.
    Ciccolini J; Serdjebi C; Peters GJ; Giovannetti E
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):1-12. PubMed ID: 27007129
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.
    Taucher V; Mangge H; Haybaeck J
    Cell Oncol (Dordr); 2016 Aug; 39(4):295-318. PubMed ID: 27060060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
    Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
    J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer.
    Tian X; Shivapurkar N; Wu Z; Hwang JJ; Pishvaian MJ; Weiner LM; Ley L; Zhou D; Zhi X; Wellstein A; Marshall JL; He AR
    Oncol Lett; 2016 Mar; 11(3):1645-1650. PubMed ID: 26998056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pancreatic Cancer Epidemiology, Detection, and Management.
    Zhang Q; Zeng L; Chen Y; Lian G; Qian C; Chen S; Li J; Huang K
    Gastroenterol Res Pract; 2016; 2016():8962321. PubMed ID: 26941789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms.
    Chand S; O'Hayer K; Blanco FF; Winter JM; Brody JR
    Int J Biol Sci; 2016; 12(3):273-82. PubMed ID: 26929734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies.
    Loong HH; Chan AC; Wong AC
    J Cancer; 2016; 7(3):268-75. PubMed ID: 26918039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma.
    Vahabi M; Dehni B; Antomás I; Giovannetti E; Peters GJ
    Cancer Metastasis Rev; 2023 Sep; 42(3):725-740. PubMed ID: 37490255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer.
    Cao R; Song W; Ye C; Liu X; Li L; Li Y; Yao H; Zhou X; Li L; Shao R
    Cancer Med; 2019 Feb; 8(2):643-655. PubMed ID: 30681288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.
    Tesfaye AA; Azmi AS; Philip PA
    Am J Pathol; 2019 Jan; 189(1):58-70. PubMed ID: 30558723
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.